论文部分内容阅读
目的:了解新型抗癫药妥泰对症状性癫的疗效。方法:病人用药前4周,填写发作日志,记录发作次数,随后单用或添加治疗,随访4个月至3年。以用药后每4周的发作次数与用药前基线比较,减少75%为有效,发作停止1年者为发作停止,以评价其药物疗效。结果:在对242例症状性癫的研究中发现妥泰治疗由于肿瘤引起的癫的发作停止率为61%,有效率为74%;头伤后癫的发作停止率为34.6%,有效率为55.7%;脑血管病所致癫的发作停止率为81.2%,有效率为90.6%;炎症后癫的发作停止率为52%,有效率为54.5%;发育障碍性癫的发作停止率为50%,有效率为64%;寄生虫所致癫的有效率为87.5%;糖尿病性癫的有效率为81.8%。结论:妥泰对症状性癫也是有效的,其中对慢性肿瘤、头伤、糖尿病等所致的癫可能具有更大的优势。
Objective: To understand the efficacy of a new antiepileptic drug, Topiramate, on symptomatic epilepsy. Methods: Patient medication for 4 weeks, fill in the seizure log, record the number of seizures, followed by single or add treatment, followed up for 4 months to 3 years. The number of seizures every 4 weeks after treatment was reduced by 75% compared with the baseline before treatment, and the onset of seizures was stopped for 1 year to evaluate the efficacy of the drug. Results: In the study of 242 cases of symptomatic epilepsy, it was found that the stopping rate of topiramate treatment for epileptic seizures caused by tumors was 61%, the effective rate was 74%; the stopping rate of epileptic seizures after head injury was 34.6%, the effective rate was 55.7%. The stopping rate of epilepsy caused by cerebrovascular disease was 81.2% and the effective rate was 90.6%. The stopping rate of epileptic seizures was 52% and the effective rate was 54.5%. The stopping rate of developing epileptic seizures was 50 %, The effective rate was 64%; the effective rate of parasite-induced epilepsy was 87.5%; the effective rate of diabetic epilepsy was 81.8%. Conclusion: Topotecan is also effective in treating symptomatic epilepsy, of which epilepsy may have more advantages for chronic tumors, head injuries and diabetes.